Tumor-Infiltrating Myeloid Cells – Using MultiOmyx™ to Distinguish between TAMs, TANs, and MDSCs in the Pancreatic Tumor Microenvironment
Literature
Read More
Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification
Literature
Read More
NeoGenomics Reports Revenue of $67.8 Million on 18.7% Clinical Volume Growth and $10.5 Million of Adjusted EBITDA in the Fourth Quarter of 2017
Press Release
Read More
Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancer
Literature
Read More
NeoGenomics Schedules its Fourth Quarter and Fiscal Year 2017 Earnings Release for February 21, 2018
Press Release
Read More
Prostatectomy-based validation of combined urine and plasma test for predicting high grade prostate cancer
Literature
Read More